Interrater Reliability of the Modified Monitoring of Side Effects Scale for Assessment of Adverse Effects of Psychiatric Medication in Clinical and Research Settings

被引:7
作者
Nugent, Katie L. [1 ]
Spahr, Erin [2 ]
Toroney, Jaimie [3 ]
Mojtabai, Ramin [4 ]
Nettles, Carrie [5 ]
Turner, Lydia W. [6 ]
Fenton, Ashley [7 ]
Spivak, Amethyst [8 ]
Cullen, Bernadette A. [4 ,9 ]
Everett, Anita [2 ]
Eaton, William W. [4 ]
机构
[1] Univ Maryland, Sch Med, Maryland Psychiat Res Ctr, Dept Psychiat, Baltimore, MD 21228 USA
[2] Johns Hopkins Bayview Med Ctr, Community Gen Psychiat Div, Baltimore, MD USA
[3] Kennedy Krieger Inst, Dept Internal Med, Baltimore, MD USA
[4] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Mental Hlth, Baltimore, MD USA
[5] Kennedy Krieger Inst, Lab Neurocognit Imaging Res, Baltimore, MD USA
[6] Lewin Grp, Falls Church, VA USA
[7] Johns Hopkins Univ, Sch Nursing, Baltimore, MD 21218 USA
[8] Univ Maryland, Francis King Carey Sch Law, Baltimore, MD 21228 USA
[9] Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA
关键词
adverse effects; psychiatric medications; rating scales; RATING-SCALE; SCHIZOPHRENIA; PREDICTORS; ADHERENCE;
D O I
10.1097/JCP.0000000000000311
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The assessment of adverse effects of psychiatric medications is important in clinical and research settings because they are often associated with medication discontinuation, symptom exacerbation, and reduced quality of life. Currently available assessment tools are either limited with regard to the number and variety of included adverse effects or are not practical for use in most clinical or research settings owing to specialized rater training required and administration length. This report describes a modification of the Monitoring of Side Effects Scale (MOSES), an established adverse effect rating scale, by adding severity anchors to improve its reliability and ease of use. Interrater reliability was good for 7 of the 8 bodily adverse effects assessed, with intraclass correlation coefficients ranging from 0.76 to 0.91 in a sample of patients with severe mental illness. This modified version of the Monitoring of Side Effects Scale holds promise as a useful tool for assessing medication adverse effects in clinical and research settings.
引用
收藏
页码:324 / 328
页数:5
相关论文
共 25 条
  • [1] [Anonymous], 2011, Stata statistical software: Release 12
  • [2] The Barnes Akathisia Rating Scale - Revisited
    Barnes, TRE
    [J]. JOURNAL OF PSYCHOPHARMACOLOGY, 2003, 17 (04) : 365 - 370
  • [3] A test of concordance between patient and psychiatrist valuations of multiple treatment goals for schizophrenia
    Bridges, John F. P.
    Slawik, Lara
    Schmeding, Annette
    Reimer, Jens
    Naber, Dieter
    Kuhnigk, Olaf
    [J]. HEALTH EXPECTATIONS, 2013, 16 (02) : 164 - 176
  • [4] A patient perspective of the impact of medication side effects on adherence: results of a cross-sectional nationwide survey of patients with schizophrenia
    DiBonaventura, Marco
    Gabriel, Susan
    Dupclay, Leon
    Gupta, Shaloo
    Kim, Edward
    [J]. BMC PSYCHIATRY, 2012, 12
  • [5] Guy W., 1976, CGI clinical global impressions
  • [6] Clinical and economic consequences of medication non-adherence in the treatment of patients with a manic/mixed episode of bipolar disorder: Results from the European Mania in Bipolar Longitudinal Evaluation of Medication (EMBLEM) Study
    Hong, Jihyung
    Reed, Catherine
    Novick, Diego
    Maria Haro, Josep
    Aguado, Jaume
    [J]. PSYCHIATRY RESEARCH, 2011, 190 (01) : 110 - 114
  • [7] Predictors of medication adherence in patients with schizophrenia and bipolar disorder
    Jonsdottir, H.
    Opjordsmoen, S.
    Birkenaes, A. B.
    Simonsen, C.
    Engh, J. A.
    Ringen, P. A.
    Vaskinn, A.
    Friis, S.
    Sundet, K.
    Andreassen, O. A.
    [J]. ACTA PSYCHIATRICA SCANDINAVICA, 2013, 127 (01) : 23 - 33
  • [8] Jordan S, 2004, Int Nurs Rev, V51, P208, DOI 10.1111/j.1466-7657.2004.00251.x
  • [9] KALACHNIK JE, 1993, J CLIN PSYCHOL, V49, P177
  • [10] Kalachnik JE, 1999, CHALLENGING BEHAVIOR OF PERSONS WITH MENTAL HEALTH DISORDERS AND SEVERE DEVELOPMENTAL DISABILITIES, P151